MX2016001030A - Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. - Google Patents

Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.

Info

Publication number
MX2016001030A
MX2016001030A MX2016001030A MX2016001030A MX2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A MX 2016001030 A MX2016001030 A MX 2016001030A
Authority
MX
Mexico
Prior art keywords
compositions
methods
desmopressin
beta
combination
Prior art date
Application number
MX2016001030A
Other languages
English (en)
Inventor
H Fein Seymour
Herschkowitz Samuel
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2016001030A publication Critical patent/MX2016001030A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La invención brinda métodos y composiciones para uso de desmopresina en combinación con un agonista del receptor beta-3-adrenérgico, los métodos y las composiciones son útiles en el tratamiento de nicturia nocturna y otros trastornos de frecuencia urinaria.
MX2016001030A 2013-07-23 2014-07-23 Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico. MX2016001030A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361857431P 2013-07-23 2013-07-23
PCT/US2014/047899 WO2015013454A1 (en) 2013-07-23 2014-07-23 Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist

Publications (1)

Publication Number Publication Date
MX2016001030A true MX2016001030A (es) 2016-10-07

Family

ID=51299056

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001030A MX2016001030A (es) 2013-07-23 2014-07-23 Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.

Country Status (11)

Country Link
US (2) US9814753B2 (es)
EP (1) EP3024474B1 (es)
JP (2) JP2016525548A (es)
KR (3) KR20210103589A (es)
CN (1) CN105579057A (es)
AU (1) AU2014293141A1 (es)
CA (1) CA2919198A1 (es)
DK (1) DK3024474T3 (es)
ES (1) ES2910361T3 (es)
MX (1) MX2016001030A (es)
WO (1) WO2015013454A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
PT2442821T (pt) * 2009-06-18 2017-09-29 Allergan Inc Administração segura de desmopressina
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EP3024474B1 (en) * 2013-07-23 2022-01-05 Serenity Pharmaceuticals LLC Compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
KR20210103590A (ko) 2013-07-23 2021-08-23 세레니티 파마슈티컬즈 엘엘씨 5-알파 환원효소 억제제와 함께 데스모프레신을 포함하는 방법 및 조성물
DK3220942T3 (da) 2014-11-20 2022-07-18 Serenity Pharmaceuticals Llc Sammensætninger omfattende lav dosis af desmopressin i kombination med en alpha-adrenerg receptorantagonist
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
WO2017210700A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
KR101877834B1 (ko) * 2017-04-27 2018-07-12 주식회사 다산제약 미라베그론의 신규한 염 및 이의 제조방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH495957A (de) 1966-09-15 1970-09-15 Ceskoslovenska Akademie Ved Verfahren zur Herstellung eines antidiuretisch wirksamen Polypeptids
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
US4405616A (en) 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
IL101243A (en) 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
DE69831421T2 (de) 1997-12-02 2006-06-22 Archimedes Development Ltd. Zusammensetzungen zur nasalen verabreichung
US7335186B2 (en) 1998-03-13 2008-02-26 Alexander George Brian O'Neil Patient controlled drug delivery device
US6558695B2 (en) 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
ES2717656T3 (es) 2000-11-30 2019-06-24 Valeritas Inc Dispositivo con microsonda amovible sustancialmente libre sobre el alojamiento
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US6945952B2 (en) 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
US7750029B2 (en) * 2002-11-07 2010-07-06 Astellas Pharma Inc. Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
JP5596252B2 (ja) * 2003-11-10 2014-09-24 アラーガン、インコーポレイテッド 低用量デスモプレシンを含有する医薬組成物
EP1706128B1 (en) 2003-12-08 2010-07-21 CPEX Pharmaceuticals, Inc. Pharmaceutical compositions and methods for insulin treatment
DE102005016981A1 (de) 2005-04-13 2006-10-19 Bayer Healthcare Ag Kombination zur Therapie bei benigner Prostatahyperplasie
JP2009520806A (ja) 2005-12-21 2009-05-28 ファイザー・プロダクツ・インク ＰＤＥ−５阻害薬と５−α還元酵素阻害薬の医薬組合せ
JPWO2007083640A1 (ja) * 2006-01-18 2009-06-11 杏林製薬株式会社 頻尿及び尿失禁の予防又は治療剤
AU2008283929B2 (en) 2007-08-06 2013-10-10 Serenity Pharmaceuticals, Llc Methods and devices for desmopressin drug delivery
CN101648017A (zh) 2008-08-12 2010-02-17 许洁 用于治疗泌尿生殖系统及下尿路疾病的联合药物组合物
EP2361092A4 (en) 2008-09-04 2012-07-11 Anthony I Rozmanith MEDICAL CARE
WO2010075327A1 (en) 2008-12-22 2010-07-01 Serenity Pharmaceuticals Corporation Desmopressin composition
NZ593613A (en) 2008-12-22 2013-02-22 Allergan Inc Intranasal desmopressin administration
PT2442821T (pt) * 2009-06-18 2017-09-29 Allergan Inc Administração segura de desmopressina
BR112012007829A2 (pt) * 2009-10-07 2015-09-22 Merck Sharp & Dohme método para tratar bexiga hiperativa, e, composição farmacêutica.
US9119878B2 (en) 2010-07-08 2015-09-01 Wellesley Pharmaceuticals, Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
US9522129B2 (en) * 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
WO2012109387A1 (en) 2011-02-08 2012-08-16 Halozyme, Inc. Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
NZ630471A (en) 2012-03-19 2016-04-29 Wellesley Pharmaceuticals Llc Extended-release formulation for reducing the frequency of urination and method of use thereof
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
GB201312155D0 (en) 2013-07-05 2013-08-21 Ucl Business Plc Therapeutic invention
EP3024474B1 (en) 2013-07-23 2022-01-05 Serenity Pharmaceuticals LLC Compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
KR20210103590A (ko) 2013-07-23 2021-08-23 세레니티 파마슈티컬즈 엘엘씨 5-알파 환원효소 억제제와 함께 데스모프레신을 포함하는 방법 및 조성물
EP3041461A4 (en) 2013-09-03 2017-05-03 G2B Pharma Inc. Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions
DK3220942T3 (da) 2014-11-20 2022-07-18 Serenity Pharmaceuticals Llc Sammensætninger omfattende lav dosis af desmopressin i kombination med en alpha-adrenerg receptorantagonist

Also Published As

Publication number Publication date
EP3024474A1 (en) 2016-06-01
JP2016525548A (ja) 2016-08-25
KR20240015735A (ko) 2024-02-05
KR20210103589A (ko) 2021-08-23
ES2910361T3 (es) 2022-05-12
JP7219736B2 (ja) 2023-02-08
AU2014293141A1 (en) 2016-02-18
US20150031613A1 (en) 2015-01-29
CA2919198A1 (en) 2015-01-29
US10568927B2 (en) 2020-02-25
CN105579057A (zh) 2016-05-11
US9814753B2 (en) 2017-11-14
US20180289769A1 (en) 2018-10-11
WO2015013454A1 (en) 2015-01-29
DK3024474T3 (da) 2022-03-28
KR20160033220A (ko) 2016-03-25
EP3024474B1 (en) 2022-01-05
JP2020109122A (ja) 2020-07-16

Similar Documents

Publication Publication Date Title
MX2016001030A (es) Métodos y composiciones que comprenden desmopresina en combinación con un agonista del receptor beta 3-adrenérgico.
IL267066B (en) Activin-actrii antagonists and their use for the treatment of bone and other disorders
SG11201705917PA (en) Low density polishing pad
EP2972349A4 (en) POLYMER POINT COMPOSITIONS AND CORRESPONDING METHODS
MX2016013280A (es) Composiciones topicas para el alivio del dolor, manufactura y uso.
MX360710B (es) Antagonistas de il17c para el tratamiento de trastornos inflamatorios.
EP2988744A4 (en) THIAZOLE SUBSTITUTED AMINOHETEROARYL COMPOUNDS TYLOSINE KINASE SPLENIC INHIBITORS
EP2947168A4 (en) THERMALLY CALIBRATED STEEL MACHINE WIRE HAVING EXCELLENT FATIGUE PROPERTIES, AND SPRING USING THE SAME
GB2528622B (en) Test bench combining high-frequency tribological stress and oligocyclic fatigue
IL256208A (en) Biomarkers associated with lsd1 inhibitors and their uses
PT3221514T (pt) Palmilha de travessa
HK1219229A1 (zh) 用於疼痛緩解而不致麻木的組合物和方法
PL2997345T3 (pl) Stanowisko badawcze do badań zmęczeniowych przy obciążeniu niskocyklowym i wysokocyklowym
SI3013855T1 (sl) Mutantne sestave faktorja VIII in metode
IL276431A (en) Treatment of the brain disorders and related symptoms
HK1246653A1 (zh) 奧那司酮延長釋放組合物和方法
IN2014CN00312A (es)
PL3452659T3 (pl) Warstwa pośrednia szyny
SG11201702051VA (en) Nickel phosphorous cmp compositions and methods
IL253349A0 (en) Borate produced in colloidal form and its use
MX2016001032A (es) Metodos y composiciones que comprenden desmopresina en combinacion con un inhibidor de 5-alfa reductasa.
GB201511162D0 (en) Kneeling pad device
MX2017006655A (es) Metodos y composiciones que comprenden desmopresina en combinacion con un antagonista del receptor alfa-adrenergico.
EP3004139A4 (en) SELECTININHIBITORS, COMPOSITION AND RELATED USES
GB2516844B (en) Kneeling pad